#Microbiome Sample Preparation Technology Industry | Explore Tumblr Posts and Blogs

rahulg1122 · 3 years

Text

Metagenomic Sequencing Market Worth $2.3 Billion by 2024

According to the new market research report "Metagenomic Sequencing Market by Workflow (Sample Preparation, Data Analysis), Product & Services (Reagents, Consumables, Instruments), Technology (Shotgun, 16s Rrna, Whole-Genome), Application (Diagnostic, Soil Microbiome) - Global Forecast to 2024", published by MarketsandMarkets™, the Metagenomic Sequencing Market is projected to reach USD 2.3 billion by 2024 from USD 1.0 billion in 2019 at a CAGR of 17.0%.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=60408643

The growth of this market is driven by factors such as the significant applications of metagenomics in various fields, the various initiatives and funding from government & private bodies for large-scale sequencing projects, and the declining cost of sequencing. The availability of cloud computing for data management is another factor providing market players with growth opportunities.

Reagents & consumables accounted for the largest share of the Metagenomic Sequencing Market, in 2018.

On the basis of products & services, the Metagenomic Sequencing Market is segmented into reagents & consumables, instruments, services, and analysis & data interpretation solutions. Of all these segments, reagents & consumables accounted for the largest share of the market in 2018. Factors such as the development and commercialization of high-quality reagents and kits and the continuous requirement of sequencing reagents by end users are expected to drive the growth of the reagents & consumables market in the coming years.

The sample processing & library preparation segment accounted for the largest share of the Metagenomic Sequencing Market in 2018.

Based on workflow, the market has been segmented into sample processing & library preparation, sequencing, and data processing & analysis. Sample processing & library preparation accounted for the largest share of the Metagenomic Sequencing Market in 2018. The large share of this segment can be attributed to the growing number of metagenome sequencing research projects being conducted, the availability of technically advanced and robust sample processing and library preparation assay kits, and the demand for efficient library preparation products.

Browse in-depth TOC on "Metagenomic Sequencing Market"

60 – Tables

30 – Figures

149 – Pages

The shotgun metagenomic sequencing technology is expected to witness the highest growth rate in the Metagenomic Sequencing Market during the forecast period.

On the basis of technology, the Metagenomic Sequencing Market is segmented into shotgun metagenomic sequencing, 16S rRNA sequencing, metatranscriptomics, and whole-genome sequencing & de-novo assembly. The shotgun metagenomic sequencing technology is expected to witness the highest growth rate in the Metagenomic Sequencing Market during the forecast period. This can be attributed to the advantages offered by shotgun sequencing over other techniques, growing adoption of shotgun metagenomic sequencing among researchers and healthcare professionals, and the increasing number of metagenomic sequencing-based research activities.

The drug discovery segment accounted for the largest share of the Metagenomic Sequencing Market in 2018.

Based on applications, the market is segmented into drug discovery, clinical diagnostics, soil microbiome applications, industrial applications, ecological and environmental applications, veterinary applications, and other applications. The drug discovery segment accounted for the largest share of the Metagenomic Sequencing Market in 2018. Growth in this market segment is mainly due to the increasing research activities for novel drug discovery, growing collaborations between market players, academic institutions, and pharmaceutical companies for drug development, and growing use of metagenomic NGS in clinical trials.

Get 10% Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=60408643

The Asia Pacific region is projected to grow at the highest CAGR during the forecast period.

On the basis of region, the market has been classified into-North America, Europe, the Asia Pacific, and the RoW. The Asia Pacific regional segment, on the other hand, is expected to grow at the highest CAGR of 18.3% during the forecast period. Growth in this market segment is mainly due to a significant focus on R&D activities as a means of broadening the scope of metagenomics applications, increasing adoption of metagenomics for diagnostics (due to the decreasing cost of metagenomics products and services), and technological developments in metagenomics genomic data analysis as well as interpretation.

The major players operating in the global Metagenomic Sequencing Market are Illumina, Inc. (US), Thermo Fisher Scientific, Inc (US), QIAGEN N.V. (Netherlands), PerkinElmer (US), Oxford Nanopore Technologies Ltd (UK), BGI Group (China), Macrogen Inc. (South Korea), GENEWIZ (US), Eurofins Scientific (Luxembourg), Novogene Corporation (China), Zymo Research Corporation (US), NuGEN Technologies, Inc (US), IntegraGen SA (France), Microsynth AG (Switzerland), and DNAStar, Inc (US).

#metagenomic sequencing market

0 notes

linhgd9 · 3 years

Text

Central Nervous System Treatment Market to Rise at an Accelerated Pace Backed by Rising Pharmaceutical Sector in North America

The global “central nervous system treatment market” is expected to gain momentum in the forthcoming years. This is attributable to the increasing prevalence of neurological disorders and the availability of advanced healthcare facilities in developed and emerging economies that propel the adoption of novel central nervous system treatment solutions globally. Fortune Business Insights published this information in its upcoming report, titled, “Central Nervous System Treatment Market Size, Share & Industry Analysis, By Drug Class (Analgesics, Anesthetics, Anticonvulsants, Antiemetics, Antiparkinson Agents), By Disease Indication (Neurovascular Disease, Degenerative Disorders, Mental Health & Trauma, Others), By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy) and regional forecast 2020-2027.”

The widespread effect of the global pandemic, COVID-19, has been felt across several economies that are facing unprecedented loss. Owing to the lockdown announced by the government agencies, several industries have been on a standstill with limited operational activities. However, a collective effort from the government as well as the industries is likely to bring the economy back on track and aid in the resumption of industrial activities.

Request a Sample Copy of the Research Report:

https://www.fortunebusinessinsights.com/enquiry/sample/central-nervous-system-treatment-market-103973

The central nervous system (CNS) is a vital system of the human body that controls major functions of the body and mind. It primarily has three significant functions that include information processing, sensory input, and motor output. The failure of CNS leads to several adverse health effects such as memory loss, weakness, numbness, lack of coordination, and loss of sight, among others. However, to counter this condition, several central nervous system treatment options are in the offing across the healthcare facilities worldwide.

An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Click here to get the short-term and long-term impact of COVID-19 on this Market.

Please visit:https://www.fortunebusinessinsights.com/central-nervous-system-treatment-market-103973

DRIVING FACTORS

Increasing Incidence of Neurological Disorders to Feed Market Growth

According to the World Health Organization (WHO), around 1.2 million adult-onset brain disorders diagnosed are due to Alzheimer disease. Additionally, over 60,000 Americans are diagnosed with Parkinson’s disease in the United States. The increasing prevalence of neurological disorders is expected to boost the adoption of advanced central nervous system treatment solutions during the forecast period. Moreover, availability of advanced healthcare facilities is expected to contribute to the global central nervous system treatmentmarket in the forthcoming years.

REGIONAL INSIGHTS

Growing Pharmaceutical Sector in North America to Accelerate Growth

Among all the regions, North America is expected to remain dominant and hold the highest position in the global central nervous system treatment market during the forecast period. This dominance is attributable to the growing pharmaceutical sector that supports the adoption of advanced central nervous system treatment solutions in the region.

On the other hand, Europe is expected to hold the second position in the market owing to the increasing demand for therapeutic drugs in the region between 2020 and 2027.

COMPETITIVE LANDSCAPE

Increasing Investment in R&D Activities by Prominent Companies to Boost Product Adoption

The global central nervous system treatment market is consolidated by the presence of major companies that are investing in R&D activities to develop novel central nervous system treatment solutions. Additionally, other key players are adopting strategies such as collaborations and partnerships that are likely to bode well for the market growth during the forecast period.

Have Any Query? Ask Our Experts:

https://www.fortunebusinessinsights.com/enquiry/sample/central-nervous-system-treatment-market-103973

Industry Development:

December 2020 – Innovent Biologics, Inc., a leading biopharmaceutical company, announced the approval of its recombinant humanized anti-VEGF monoclonal antibody drug, BYVASDA by the National Medical Products Administration (NMPA) of China. The company reports that the central nervous system treatment solution is an effective therapeutic drug that can be used for treating glioblastoma patients.

List of the Companies Profiled in the Global Market for Central Nervous System Treatment:

Eli Lilly and Company

Pfizer Inc.

Otsuka America Pharmaceutical, Inc.

Biogen

AstraZeneca

Novartis AG

Takeda

Merck & Co., Inc.

Teva Pharmaceutical Industries Ltd.

Johnson & Johnson Services, Inc.

Others

About Us:

Fortune Business Insights

offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights

we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Fortune Business Insights

Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email:[email protected]

Fortune Business Insights

LinkedIn | Twitter | Blogs

Related Reports :

Feeding Tubes Market

Feeding Tubes Market Size

Feeding Tubes Market Share

Feeding Tubes Market Trends

Feeding Tubes Market Growth

Feeding Tubes Market Analysis

Feeding Tubes Market Business Opportunities

Feeding Tubes Market Key Players

Feeding Tubes Market Demand

Feeding Tubes Market Competitive Landscape

Microbiome Therapeutics Market Segments

Microbiome Therapeutics Market Overview

Microbiome Therapeutics Industry

Microbiome Therapeutics Market Stastistic

Microbiome Therapeutics Market Devlopment Strategy

Microbiome Therapeutics Market Future Growth

Microbiome Therapeutics Market Research Methodology

Microbiome Therapeutics Market Drivers

Microbiome Therapeutics Market Manufacturers

Microbiome Therapeutics Market Revenue

from NeighborWebSJ https://ift.tt/3zLz5yc via IFTTT

from WordPress https://ift.tt/3xLcGPH via IFTTT

#WordPress

0 notes

newstrends1 · 4 years

Text

Multiplex Assays Market Revenue, Global Forecast, Cost, Key Participants and Key Players – MESO SCALE DIAGNOSTICS, LLC., QIAGEN, PerkinElmer Inc. , Illumina, Inc. , Olink

Multiplex Assays Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings with data Tables for historical and forecast years represented with Charts & Graphs spread through 350 Pages with easy to understand detailed analysis. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing. The study highlights detailed assessment of the Market and display Multiplex Assays market sizing trend by revenue & volume (if applicable), expert opinions, current growth factors, facts, and industry validated market development data.

Global multiplex assays market is expected to reach a healthy CAGR of 7.5% in the forecast period of 2019 to 2026. The new market report contains data for historic years 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Download Free Sample Copy @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-Multiplex Assays-market

Product launch:

In June 2018, QIAGEN (Germany) launched the QIAseq 16S/ITS Panels and UCP Multiplex PCR Kit. This kit was launched along with a new generation of reagents that allows the most accurate quantification and qualitative analysis from complex microbiome samples. This product provides a comprehensive and robust profiling of bacterial and fungal communities. With this launch, one more product got added to the company’s product portfolio.

In May 2018, Bio-Rad Laboratories, Inc. launched the Bio-Plex Pro Human Cytokine Screening Panel. This product is the first validated high-performance multiplex assay on the market. The panel has the ability to identify and quantify 48 different analytes. This is applicable for identification and estimation of analytes for heart disease, autoimmunity and allergy, cancer, and many other conditions. Launching this product helped the company in increasing their product portfolio.

In June 2018, QIAGEN launched the QIAseq 16S/ITS Panels and UCP Multiplex PCR Kit. This kit was launched with a new generation of reagents to allow the most accurate microbial community profiling from complex microbiome samples. This product provides comprehensive and robust profiling of bacterial and fungal communities. With this launch one more product got added to company’s product portfolio.

In May 2017, Bio-Rad Laboratories, Inc. launched the Bio-Plex Pro Human Apolipoprotein Panel. This product has 10-plex panel that allows researchers to detect and quantify quickly key human apolipoproteins associated with cardiovascular disease, especially within the statin pathway. The panel offers the largest number of apolipoproteins on the market. It is one of the easiest way for detection for the problems related to cardiovascular and others and with this company has added one more product in their product portfolio for serving it to their customer in market.

In August 2017, Quanterix Corporation announced expansion for its single molecule array, or Simoa, technology platform portfolio by launching the new Quanterix SR-Plex benchtop instrument. Digital health revolution and life science research increased multiplexing capabilities.

Relevant features of the study that is being offered with major highlights from the report:

1) Which companies are profiled in current version of the report? Can list of players be customizing based on regional geographies we are targeting.

Some of the prominent participants operating in this market are BD, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Cepheid, Siemens AG, Hologic Inc., Luminex Corporation. , MESO SCALE DIAGNOSTICS, LLC., QIAGEN, PerkinElmer Inc. , Illumina, Inc. , AGENA BIOSCIENCE, INC. , Olink , Randox Laboratories Ltd., Bio-Techne. , Agilent Technologies, Agilent Technologies, Sysmex Corporation and among others..

2) What all regional break-up covered? Is it possible to add specific country or region of interest?

Currently, research report gives special attention and focus on following regions: Asia-Pacific, South America, North America, Europe and & Middle East & Africa

3) Can Market be broken down by different set of application and types?

Additional Multiplex Assays Market segmentation / Market breakdown is possible subject to data availability, feasibility and depending upon timeline and toughness of survey. However a detailed requirement needs to be prepared before making any final confirmation.

By Technology (qPCR, dPCR), Products & Services (qPCR Products & Services, dPCR Products & Services), Application (qPCR Applications, dPCR Applications), End User (qPCR End Users, dPCR End Users), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)

MAJOR TOC OF THE REPORT

Chapter One: Multiplex Assays Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Multiplex Assays Market Competition, by Players

Chapter Four: Global Multiplex Assays Market Size by Regions

Chapter Five: North America Multiplex Assays Revenue by Countries

Chapter Six: Europe Multiplex Assays Revenue by Countries

Chapter Seven: Asia-Pacific Multiplex Assays Revenue by Countries

Chapter Eight: South America Multiplex Assays Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Multiplex Assays by Countries

Chapter Ten: Global Multiplex Assays Market Segment by Type

Chapter Eleven: Global Multiplex Assays Market Segment by Application

Get Detailed Toc @ https://www.databridgemarketresearch.com/toc/?dbmr=global-Multiplex Assays-market

Points Which Are Focused In the Report

Industry Chain Suppliers of Digital PCR market with Contact Information

The key findings and recommendations highlight crucial progressive industry trends in the Digital PCR Market, thereby allowing players to develop effective long term strategies

To analyze opportunities in the market for stakeholders by identifying the high-growth segments of the Digital PCR market

To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, and detail the competitive landscape for market leaders

To understand the future outlook and prospects for Digital PCR market analysis.

Reasons for Buying this Multiplex Assays Report

1. Multiplex Assays market report aids in understanding the crucial product segments and their perspective.

2. Initial graphics and exemplified that a SWOT evaluation of large sections supplied from the Multiplex Assays industry.

3. Even the Multiplex Assays economy provides pin line evaluation of changing competition dynamics and retains you facing opponents.

4. This report provides a more rapid standpoint on various driving facets or controlling Multiplex Assays promote advantage.

5. This worldwide Multiplex Assays report provides a pinpoint test for shifting dynamics that are competitive.

Access Full Reports @ https://www.databridgemarketresearch.com/reports/global-multiplex-assays-market

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like West Europe, North America, MENA Countries, LATAM, Southeast Asia or Asia Pacific.

About Us:

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

Browse Related Reports@

Gene Synthesis Market

Multiplex Assays Market

#Multiplex Assays Market

0 notes

syndicatemarketresearch29 · 5 years

Text

Global Microbiome Drugs Market 2020 Global Analysis, Opportunities and Forecast to 2026

The Global Microbiome Drugs Market report explores the essential factors such as industry situations, market demands, market players adopted business strategies and their growth scenario. The Microbiome Drugs market report offers a forecast of revenue, CAGR, and cumulative revenue (covering USA, EU, China, Japan, India and etc). The Market study gives data with n-number of tables and figures examining the Microbiome Drugs, the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2026. The market is growing with technological innovation, competition and M&A activities in the industry are offering specific application products for varied end-users. Key manufacturers of Global Microbiome Drugs Market, listed here are Pfizer, Second Genome, Seres Therapeutics, MaaT Pharma, Enterome Bioscience, MicroBiome Therapeutics, Ritter Pharmaceuticals, Rebiotix, OpenBiome.The report provides an overview of the players operating in the market, the strategies deployed by them to gain competitive advantage, the annual revenue generated by them in the historical years, and their relevant business segment revenue.

Request for Sample Report @ https://www.syndicatemarketresearch.com/market-analysis/microbiome-drugs-market.html#sample

The Microbiome Drugs market delivers a wide array of primary and secondary data with respect to regional and global market. In-depth analysis of numerous components has been studied in the report including supply and demand Figures, cost, price, revenue, gross margins, current geographical zones, technology, demand-supply and consumption. The market study focuses on industry dynamics including driving factors to provide the key elements fueling the current market growth. The report also identifies restraints and opportunities to identify high growth segments involved in Microbiome Drugs market. In addition to this, the study provides Porters five forces analysis, PESTEL analysis and industry chain analysis of the Microbiome Drugs market to gain the impact of various factors such as bargaining power of suppliers, competitive rivalry, threat of new entrants, threat of substitutes, and bargaining power of buyers on the growth of Microbiome Drugs market.

This report studies Microbiome Drugs in global market with production, revenue, consumption, sales, import and export, market share and growth rate of forecast period 2019-2025. The Microbiome Drugs market report gathered information holds important information which has been shared in a precise and structured manner using a number of monographs, tables, pie charts and bar-graphs. In the end, the report makes some important proposals for a new project of Microbiome Drugs market before evaluating its feasibility. The solid research on the Microbiome Drugs Market is prepared with the aim to meet the requirements of the customer in terms of the availability of data, analytics, statistics, and an accurate forecast market.The market report also presents the landscape and a corresponding detailed analysis of the major players operating in the market. The market report analyses the market potential for each geographical region based on the growth rate, consumer buying patterns, and market demand and supply scenarios.

Market Analysis by Regions: Each geographical region is analyzed as Sales, Market Share (%) by Types & Applications, Production, Consumption, Imports & Exports Analysis, and Consumption Forecast. USA, Europe, Japan, China, India, Southeast Asia, South America, South Africa, Others.

Segment by Type, Global Microbiome Drugs Market can be split into: Probiotics, Prebiotics, Small Molecules, Biological Drugs, Other

Segment by Applications, Global Microbiome Drugs Market can be split into: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other

Reasons to Purchase this Microbiome Drugs market Report:

1) Analyzing the outlook of the market with the recent trends and SWOT analysis 2) Microbiome Drugs Market dynamics scenario, along with growth opportunities of the market in the years to come 3) Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects 4) Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the Microbiome Drugs market. 5) Market value (USD Million) and volume (Units Million) data for each segment and sub-segment 6) Competitive landscape involving Microbiome Drugs market share of major players, along with the new projects and strategies adopted by players in the past five years 7) Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major Microbiome Drugs market players

The Microbiome Drugs market report provides answers to the following key questions:

- What will be the Microbiome Drugs market size and the growth rate in 2025? - What are the main key factors driving the global Microbiome Drugs market? - What are the key market trends impacting the growth of the global Microbiome Drugs market? - Which Trending factors influencing the market shares of the top regions across the globe? - Who are the key market players and what are their strategies in the global Microbiome Drugs market? - What are the market opportunities and threats faced by the vendors in the global Microbiome Drugs market? - What industrial trends, drivers and challenges are manipulating its growth? - What are the key outcomes of the five forces analysis of the global Microbiome Drugs market?

Inquiry for Buying Repor @ https://www.syndicatemarketresearch.com/inquiry/microbiome-drugs-market

In conclusion, Microbiome Drugs market report presents the descriptive analysis of the parent market supported elite players, present, past and artistic movement information which is able to function a profitable guide for all the Microbiome Drugs Industry business competitors.Our expert research analyst’s team has been trained to provide in-depth market research report from every individual sector which will be helpful to understand the industry data in the most precise way.

#Microbiome Drugs Microbiome Drugs Market Microbiome Drugs Market 2020 Global Microbiome Drugs Market 2020 Microbiome Drugs Market Growth Mic

0 notes

researchtrendingnews · 4 years

Text

Bioburden Testing Market Strategic Insights and key Business Influencing Factors | Major Players – ., Merck KGaA, SGS S.A., BD., Merck & Co., Inc., North American Science Associates Inc.

Bioburden Testing Market is the measurement method on medical devices, raw materials or packages of feasible microorganisms. The method enables to determine parameters to guarantee the safety and efficiency of medical devices. It further assists in the regular surveillance of raw materials, parts and installation procedures in the manufacturing system. Bioburden screening is used for the evaluation of drying procedures and the packaging of products is carried out to guarantee safety.

Europe bioburden testing market is registering a substantial CAGR in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. The rise in the market can be attributed due increasing using of bioburden screening for quality control in medical, biotechnological and pharmaceutical goods and increasing concern among people about bioburden screening due to microbial contamination.

Get Sample Report at :

https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-bioburden-testing-market

Competitive Analysis: Europe Bioburden Testing Market

Few of the major market competitors currently working in the Europe bioburden testing market are Charles River, Pacific Bio labs, Inc., Merck KGaA, SGS S.A., BD., Merck & Co., Inc., North American Science Associates Inc., Nelson Laboratories, LLC, Dynatec Labs, Applied Technical Services, Thermo Fisher Scientific, bioMérieux SA, among others.

Key Pointers Covered in the Europe Bioburden Testing Market Trends and Forecast to 2026

Europe Bioburden Testing Market New Sales Volumes

Europe Bioburden Testing Market Replacement Sales Volumes

Europe Bioburden Testing Market Installed Base

Europe Bioburden Testing Market By Brands

Europe Bioburden Testing Market Size

Europe Bioburden Testing Market Procedure Volumes

Europe Bioburden Testing Market Product Price Analysis

Europe Bioburden Testing Market Healthcare Outcomes

Europe Bioburden Testing Market Cost of Care Analysis

Europe Bioburden Testing Market Regulatory Framework and Changes

Europe Bioburden Testing Market Prices and Reimbursement Analysis

Europe Bioburden Testing Market Shares in Different Regions

Recent Developments for Europe Bioburden Testing Market Competitors

Europe Bioburden Testing Market Upcoming Applications

Europe Bioburden Testing Market Innovators Study

Get Detailed TOC:

https://www.databridgemarketresearch.com/toc/?dbmr=europe-bioburden-testing-market

Scope of the Bioburden Testing Market

Europe Bioburden Testing Market By Product ( Consumables, Instruments), Test Type ( Aerobic Count Testing, Anaerobic Count Testing, Fungi/Mold Count Testing, Spore Count Testing), Application ( Raw Material Testing, Medical Device Testing, In-Process Material Testing, Sterilization Validation Testing, Equipment Cleaning Validation), End User ( Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, Contract Manufacturing Organizations, Manufacturers of Food & Beverage and Agricultural Products, Microbial Testing Laboratories), country (Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe) - Industry Trends and Forecast to 2026

Bioburden testing is the measurement method on medical devices, raw materials or packages of feasible microorganisms. The method enables to determine parameters to guarantee the safety and efficiency of medical devices. It further assists in the regular surveillance of raw materials, parts and installation procedures in the manufacturing system. Bioburden screening is used for the evaluation of drying procedures and the packaging of products is carried out to guarantee safety.

Market Segmentation: Europe Bioburden Testing Market

Europe Bioburden Testing Market growing recognition of the medicinal capacity of stem cells in efficient disease management contributes to the development of the industry.

In October 2018, SGS SA has purchased INTER-BASIC RESOURCES, INC. (IBR), a non-clinical contract research organization (CRO). IBR Inc. is a specialist in state-of - the-art experimentation and biopharma technologies for the building of biologics, biosimilar and antibodies and provides multiple screen monitoring and electron tracking facilities. With this purchase, SGS SA would develop its filtration facilities and grow its client profile and client facilities.

In June 2018, QIAGEN announced the introduction of the QIAseq 16S / ITS Panels and the UCP Multiplex PCR Kit with a fresh class of reagents to allow the most precise microbial community profiling of complicated microbiome samples. The fresh QIAGEN devices prevent internal bias in PCR and NGS library preparing with inhibitor-resistant PCR and small bioburden reagents screened for bacterial and fungal DNA contamination.

Reasons to Purchase this Report:

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

Regions/Countries that are expected to witness the fastest growth rates during the forecast period.

The latest developments, market shares, and strategies that are employed by the major market players.

Speak to Author :

https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=europe-bioburden-testing-market

Key insights in the report:

Complete and distinct analysis of the market drivers and restraints

Key Market players involved in this industry

Detailed analysis of the Market Segmentation

Competitive analysis of the key players involved

About Us:

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

Bioburden Testing Market Similar Report Here:

Biomedical Materials Market

Direct-to-Consumer (DTC) Genetic Testing Market

#Bioburden Testing Market #Bioburden Testing Market share #Bioburden Testing Market size #Bioburden Testing Market trends #Bioburden Testing Market news #Bioburden Testing Market growth #Bioburden Testing Market report

0 notes

shapesnnsizes · 6 years

Text

RHR: Is High Fat Healthy for the Gut Microbiota?

In this episode, we discuss:

The problems with nutritional research

Why correlation isn’t causation

The Bradford Hill criteria

The healthy-user bias

Why diet quality matters

The type of diet that can impact gut flora

Why you should take nutritional studies with a grain of salt

Show notes:

“Will a Low-Carb Diet Shorten Your Life?” by Chris Kresser

Spurious Correlations, by Tyler Vigen

“Red Meat and TMAO: Cause for Concern, or Another Red Herring?” by Chris Kresser

“RHR: You Are What Your Bacteria Eat: The Importance of Feeding Your Microbiome—With Jeff Leach”

The American Gut Project

“RHR: Is a Disrupted Gut Microbiome at the Root of Modern Disease?—With Dr. Justin Sonnenburg”

“The Challenge of Reforming Nutritional Epidemiologic Research,” by John Ioannidis

youtube

[smart_track_player url="http://traffic.libsyn.com/thehealthyskeptic/RHR_-_Is_High_Fat_Healthy_For_the_Gut_Microbiota.mp3" title="Reader Question - Is High Fat Healthy for the Gut Microbiota? " artist="Chris Kresser" ]

Hey, everybody, Chris Kresser here. Welcome to another episode of Revolution Health Radio. This week, we're actually going to do a reader-submitted question. I don't know when the last time I did one of these. It’s been quite a while. We've had a lot of fascinating interviews with guests that I hope you've enjoyed, but today, we're going to take a question from Carrie, so let's give that a listen.

“Hi, Chris, Carrie Bennett from Carrie B Wellness. I have a question when it comes to a high-fat diet and the health of the gut microbiome when I’m coaching my nutrition clients. After reading the Sonnenburgs’ book about gut health and the gut microbiome, it seems to be that their recommendation is that fat can change the gut microbiota in a negative way. I’m just wondering how you view this in light of a Paleolithic/primal-style diet. I’m wondering if the studies that they’re referencing are utilizing poor fat sources as opposed to high-quality, pastured or grass-fed animal fats, and just your take on it. Is high fat healthy for the gut microbiota? Thanks for any information you can provide.”

Okay, great question, Carrie. Thanks so much for sending it in. I'm going to answer that specifically, but I also want to use it as a springboard for a general discussion of problems with nutritional research.

The Problems with Nutritional Research

The first issue is that most of the research related to a high-fat diet and the effects on the gut microbiome have been done in rodents. While rodent research is certainly valuable and there's a lot that we can learn from it, the results don't necessarily apply to humans, especially in the case of a high-fat diet. In the rodent research, the most common high-fat diet uses highly processed and refined fats like corn and soybean oil. Now that very well may apply to many Americans who are eating a high-fat diet because if they're eating out at restaurants or even stores with prepared foods or they're eating a lot of packaged and processed and refined foods, then many of those are going to contain industrial seed oils like corn, soybean, cottonseed, safflower and sunflower oils, and those oils have a different effect on the gut microbiome than some traditional fats would.

Is a high-fat diet bad for your gut health? Not necessarily. Check out this episode of RHR for more on how fat impacts your gut, and find out why you can’t always trust the latest research.

In humans, the research correlating high-fat diets with changes to the gut microbiome is almost exclusively observational, as far as I know, which means that it suffers from many of the issues that I detailed in my recent article critiquing the study, which claims to find that low-carb diets shorten our lifespan. That was just a train wreck of a study, and I went through it kind of point by point. If you haven't had a chance to check that out, you can probably just Google “kresser low-carb diet shortens lifespan” and you'll find it. But I'll just briefly highlight some of the main points from that article as it relates to this question that Carrie sent in.

Why Correlation Isn't Causation

The first is the most obvious, at least if you've been following my work or this field for any length of time, and that is that correlation is not causation. An observational study just follows groups of people and examines certain variables like their diet or their lifestyle, and then they look for associations between those variables.

For example, in this case, they would look and see that people who ate a high-fat diet tended to have worse gut microbiota. But the first thing you learn if you take a research methodology class in college or grad school is that when two variables are associated together, that doesn't mean that one is causing the other. That's what the phrase “correlation is not causation” means, and there are a lot of kind of silly examples that are used to make this point.

If you consider the statement, “The more firefighters that are sent to a fire, the more damage gets done,” that's obviously a ridiculous statement, right? That's not how it works. It's not that more firefighters are causing the damage. It's that when fires are worse, more firefighters are required to fight the fire so, in that example, the causation would be reversed.

Another one is children who get tutored get worse grades than children who don't get tutored. Again, the causality there is reversed. The children who are not getting good grades in the first place are the ones that are more likely to hire a tutor, or at least their parents will.

There are a lot of examples like that just to make the point that you have to be very careful with assuming that two variables that are correlated together are, one is causing the other. There's actually a whole website that's dedicated to kind of mocking this assumption that unfortunately is very common in the mainstream media, and I'll come back to that in a second. It's a page on someone's website, Tyler Vigen, I'm not sure if I'm pronouncing that right. It's called “spurious correlations” and I'm not sure where he found all this stuff, but he went and found correlations that are just ridiculous.

For example, U.S. spending on science, space, and technology correlates with suicides by hanging, strangulation, and suffocation at 99.8 percent, which is almost a perfect correlation, 100 percent being perfect. I think we can all agree it's pretty obvious that U.S. spending on science, space, and technology is not causing suicides by hanging, strangulation, or suffocation or vice versa.

Another one of my favorites is the divorce rate in Maine correlates with per capita consumption of margarine at 99.3 percent. Again, it's obvious that there is no causality, there even though those two variables are highly correlated.

This is really critical to keep in mind when you’re looking at any observational study because observational studies were never designed to prove causality or to show that one variable is causing another. To do that, we need a randomized controlled trial.

The Bradford Hill Criteria

There are certain situations where it's not practical to do a randomized controlled trial, and we have to do our best to apply certain criteria to the observational or epidemiological data to at least increase the probability of determining whether there's a causal relationship, and these are referred to as Bradford Hill criteria.

These were originally published in 1965, if I remember correctly, and they include a number of different criteria, like the strength of the relationship, whether the relationships are connected together in time, and several other factors that when you put them all together, if those criteria are met, it significantly increases the likelihood that there is a causal relationship. But that's not done in many of these studies. In fact, many epidemiologists, especially 10, 20, 30 years ago, were sounding the alarm and saying, “Look, if we do observational study, if the risk is not at least two or three times higher…,” let's say we're talking about a high-fat diet microbiota, “…if you don't see at least two- or three- or even higher-fold risk, that a high-fat diet is contributing to worse microbiota,” then we can't really even—we might as well just not even pay attention, that these small relative increases in risk, like 15 percent or 30 percent or even 50 percent higher relative risk in observational research, are not strong enough to really show us that there's anything that we should be investigating. You want to see at least 200 or 300 percent higher risk.

I think in the cigarette smoking–lung cancer studies, it was like 3,000 percent higher. If you see variables correlated and one is leading to a 3,000 percent higher risk of something else, then yes, that's something that you're going to pay a lot of attention to and ideally do a randomized controlled trial for. That's not ethical with smoking and that's a good example where you use things like the Bradford Hill criteria to try to suss out whether there is a causal relationship. But in many of these observational studies that are being published, you'll see references to like a 10, 20, 30 percent increase, and that's just almost impossible to differentiate from the noise in a big sample of people.

The Healthy-User Bias

Any observational studies that have showed that people who eat high-fat diets have inferior gut microbiota or just showing correlation between those two variables, they do not prove that their high fat intake is the cause of the poor gut microbiota. Why? Well, because of the phenomenon known as the healthy-user bias, which I've written about and talked about on the show quite a bit.

People who engage in a behavior that's perceived as healthy are more likely to engage in other behaviors that are also perceived as healthy and vice versa. Because fat has been perceived as unhealthy for so many years, on average, people in studies that eat more fat—and this is especially true in the 80s, 90s and the 00s—people that eat more fat will be more likely to:

Smoke

Drink too much

Not exercise

Eat too much sugar

Not eat fresh fruits and vegetables, etc.

There have been many studies that have shown that to be true, that, on average, if you take a baseline population of people who have a higher fat intake or higher red meat intake or higher saturated fat intake specifically, and you compare them to another group at baseline who has lower fat intake or lower intake of red meat, you will see that, yes, that actually is true, that the group with the lower fat intake tends to smoke less, drink less, exercise more, and engage in other behaviors that are perceived as healthy because we've been told for 50 years that fat is bad for us and meat is bad for us.

In an ideal world, an observational study would control for all of those potential confounding factors like smoking or drinking too much or not exercising. But in the real world, that rarely happens, and even when some factors are controlled for, there are inevitably factors that are not controlled for and may not even be on the radar of the researchers.

For example, we know that people’s gut microbiota actually may affect how they process, digest, and absorb red meat and what the effects of red meat might be. A few years back, you might remember, there was a lot of brouhaha about TMAO, which is a compound that is associated with a higher risk of heart disease, and some studies found that people who eat red meat have higher levels of TMAO because it's made from carnitine, which is in red meat. When I looked more deeply at that study, and I wrote about this, it became clear that there was no attempt to control for the gut flora of the people who were eating the meat.

If you take someone who is on a Paleo type of diet who's eating a lot of nutrient-dense, whole foods, fresh vegetables and fruits, nuts and seeds, starchy tubers that are all high in fiber, they would have a phenomenal gut flora in that case versus someone whose intake of meat consists of burgers, KFC, sandwiches on white bread, and the typical American Diet, their gut flora is probably going to be seriously impaired. The way that those two different people respond to red meat and then subsequent TMAO production will be completely different. And that is not being controlled for in any studies that I know of.

Why Diet Quality Matters

The other problem is that these studies often don't consider diet quality. I alluded to this before. If you consider two hypothetical people, a person who's on a low-carb diet that eats primarily highly refined fats like industrial seed oils found in processed foods and foods cooked in restaurants, or a person who's on a low-carb diet that eats primarily natural fats from fresh whole foods like meat and fish, avocados, nuts, seeds, etc., that are prepared at home, is it logical to predict that these two people will enjoy the same health, the same protection from disease in the same lifespan? Of course not. Yet that is exactly what most of these observational studies assume. They all suffer from what is called “nutritionism,” which is a reductionist idea that a nutrient is a nutrient, a carbohydrate is a carbohydrate, a fat is a fat, a protein is a protein, a calorie is a calorie. Virtually every study, with some notable exceptions, doesn’t pay any attention to the quality of the nutrients that are being consumed.

In order to really determine whether a high-fat diet affects the health of the gut microbiome independently of any of the other factors that we've mentioned, ideally you'd recruit a group of people, you’d lock them up in a metabolic ward where you can control all of the other variables, and you would get them to follow a nutrient-dense, whole-foods diet, so they would all be eating fresh, whole, nutrient-dense foods. But one group would eat a lower-fat diet and one group would eat a higher-fat diet, and then you would observe them over a period of whatever period was deemed appropriate, and you would watch for changes. In that example, you’d really be more comparing apples to apples and you'd be isolating the variable of fat intake, and ideally you would have them consuming the same kinds of fats, so that didn't become a confounding factor. But as you might suspect, that would be an extremely expensive study. It's almost certainly never going to happen because most of those kinds of studies at this point are funded by drug companies or from pharmaceutical companies. There's no reason that they would do that, and public health funding for studies like that, especially very expensive studies like that, is declining, not increasing.

The Type of Diet That Can Impact Gut Flora

Having said all of that, I will point out that I think there are at least some lines of evidence suggesting that, at least in some cases, a very-low-carb or ketogenic diet may not be optimal for the gut flora over the long term. I talked about this with Jeff Leach I think several years ago now. He is one of the scientists that works on the American Gut Project, which is one of the first projects to really set out to sequence the gut microbiome, and he sent me some early results from people who had sent in stool samples to be analyzed by American Gut who were self-identified with a very-low-carb or ketogenic diet. He had noticed that there were some patterns of gut flora in those people that were not optimal.

Now you have to take this with a huge grain of salt because these were not controlled studies. The same sort of observational confounding factors could be present here. There could be a selection bias. I mean, this is not a controlled study at all, but as I discussed with Dr. Justin Sonnenburg from Stanford on my podcast a few years back, we know what feeds the beneficial gut microbiota. They're called microbiota-accessible carbohydrates, or MACs, as he calls them, and certainly non-starchy vegetables contain some of those fibers that feed beneficial bacteria. But sodas, starchy plants, and fruits, which would be eliminated on a keto or a very-low-carb diet, and so do some foods like legumes and whole grains, which have their own issues which he's talked about. But the point being that on a very-low-carb or keto diet, in some cases for some people, depending on how they go about it, their fermentable fiber intake would be lower and they may actually experience some consequences from that in terms of their gut flora.

Oftentimes with patients in the clinic, if they're on a keto or very-low-carb diet, we might actually suggest that they do whatever they can to increase their intake of fermentable fiber that's compatible with the keto approach and/or we might also suggest that they take some supplemental fermentable fibers, noncaloric prebiotic supplements, things like lacto-oligosaccharides, FOS, non-starch polysaccharides, soluble fibers, and resistant starches, all of which can help feed the beneficial gut bacteria.

Why You Should Take Nutritional Studies with a Grain of Salt

I think the takeaway here, as it so often is with these kinds of studies, is take them with a huge grain of salt because in the case of nutritional epidemiology or observational research, they are so problematic that some very prominent, well-respected, even famous epidemiologists like Dr. John Ioannidis at Stanford Medical School have come out recently, and he's been sounding this alarm for years. He wrote a recent editorial called “The Challenge of Reforming Nutritional Epidemiologic Research.” This was published in JAMA just now in late August of 2018, and I'm just going to read you a couple little choice bits.

The first sentence is, “Some nutrition scientists and much of the public often consider epidemiologic associations of nutritional factors to represent causal effects that can inform public health policy and guidelines.” When you see a study that says, “Low-carb diet increases your risk of death by 30 percent,” that's what he's talking about here. “However, the emerging picture of nutritional epidemiology is difficult to reconcile with good scientific principles. The field needs radical reform.” And he goes on to explain why nutritional epidemiology or observational research should really never be used to inform public policy because as I said before, it's just a way of generating hypotheses. It's not a way of proving causality, and every researcher knows this.

Any science reporter should know it, and when researchers report their results to the media, most do say, “This doesn't indicate that there's a causal relationship.” And yet, the media doesn't like that nuance. They want headlines that are flashy and will get people to click on them, so the way it's reported inevitably and wrongly makes it seem like a causal relationship has been established, and then you get people changing their diet based on those headlines. You even get public policy and dietary guidelines for whole countries being based on these observational studies that were never designed to inform public policy.

I think this is a huge issue. I'll be writing, actually, in the near future a lengthy critique of observational data in nutrition and how it has, really, I think, caused a lot of harm over the last 30 to 40 years in terms of creating confusion amongst the general public and medical professionals and leading us astray with our dietary guidelines and actually encouraging a focus on nutritionism and reductionism, where we just think in terms of macronutrients and quantity of them, like how many carbs and how much protein and how much fat versus the quality of the diet that we should be eating. That's really what is most important.

If we all just ate real food—forget about Paleo, keto, high-carb or low-carb anything. If we all just ate real food that didn't come out of a bag or box, we would not be in the position that we're in today. This is real harm that this approach has caused over the past several decades, and I think we really need to address that in order to move forward.

Okay, everybody, thanks for listening. I hope this was helpful. Carrie, thanks again for sending in your question, and those of you who would like to send a question in, that’s chriskresser.com/podcastquestion, and we’ll see you next time.

The post RHR: Is High Fat Healthy for the Gut Microbiota? appeared first on Chris Kresser.

0 notes

denisalvney · 6 years

Text

RHR: Is High Fat Healthy for the Gut Microbiota?

In this episode, we discuss:

The problems with nutritional research

Why correlation isn’t causation

The Bradford Hill criteria

The healthy-user bias

Why diet quality matters

The type of diet that can impact gut flora

Why you should take nutritional studies with a grain of salt

Show notes:

“Will a Low-Carb Diet Shorten Your Life?” by Chris Kresser

Spurious Correlations, by Tyler Vigen

“Red Meat and TMAO: Cause for Concern, or Another Red Herring?” by Chris Kresser

“RHR: You Are What Your Bacteria Eat: The Importance of Feeding Your Microbiome—With Jeff Leach”

The American Gut Project

“RHR: Is a Disrupted Gut Microbiome at the Root of Modern Disease?—With Dr. Justin Sonnenburg”

“The Challenge of Reforming Nutritional Epidemiologic Research,” by John Ioannidis

youtube

The Problems with Nutritional Research

Is a high-fat diet bad for your gut health? Not necessarily. Check out this episode of RHR for more on how fat impacts your gut, and find out why you can’t always trust the latest research.

Why Correlation Isn't Causation

The Bradford Hill Criteria

The Healthy-User Bias

Smoke

Drink too much

Not exercise

Eat too much sugar

Not eat fresh fruits and vegetables, etc.

Why Diet Quality Matters

The Type of Diet That Can Impact Gut Flora

Why You Should Take Nutritional Studies with a Grain of Salt

The post RHR: Is High Fat Healthy for the Gut Microbiota? appeared first on Chris Kresser.

RHR: Is High Fat Healthy for the Gut Microbiota? published first on https://chriskresser.com

0 notes

merryjain12-blog · 6 years

Text

Global Urinalysis Market 2018 Industry Trends, Sales, Supply, Demand, Analysis, Growth Factor & Forecast to 2025

Global Urinalysis Market

Urinalysis is a series of tests of urine to diagnose a common condition or diseases. Urinalysis is generally done to diagnose chronic diseases in its early stage, such as diabetes, hepatitis, chronic kidney disease (CKD) and urinary bladder cancer. Biological tests like RBC’s, WBC’s, Bacteria, or crystal test, biochemical test like Acidity, or pH, Protein, Glucose, Bilirubin test are performed to diagnose different conditions. Dipstick test is performed to check the concentration of certain constituents present in the urine. Urinalysis is generally carried out in routine medical checkups, pregnancy tests and pre-surgical preparations to treat various ailments.

Global Urinalysis Market According to Data Bridge Market Research new Market report, By Product Type (Consumables and Instruments), By Test Type (Biochemical Urinalysis, Sediment Urinalysis), By Application (Disease Diagnosis, Pregnancy Tests)By End Users (Pharmaceutical and Biotechnology Companies and Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast Period is projected to reach USD 2.54 Billion by 2025, at a CAGR of 7.30% during the forecast period of 2018 to 2025

What Is the Essential of “Global Urinalysis Market” In Medical device Industry.? How It Is Increasing The Market Growth?

The most common antibiotic treatment in kidney is urinary tract infection, its ratio is 1 is to 3 in women get. Cystitis is another common infection caused by the bacteria while other reasons responsible for this are radiotherapy and certain chemicals. Women are more prone to cystitis then males. Cystitis occurs generally in 4 out of 100 pregnant women.

For Urinalysis, instruments and consumables such as reagent kits, rapid test kits, analyzers, dipsticks, containers, and pipettes are required.

To Get a Sample Report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-urinalysis-market

Definition:

The urinalysis test is a method to detect wide range of disorders like urinary infection, kidney diseases, and diabetes in the urine. It is a convenient and effective method to analyze urine sample to detect diabetes, urinary tract infection, and kidney diseases.

For Customized Reports and Discounts, Mail us at @ [email protected]

Major Market Competitors:

Some of the major players operating in urinalysis market are Beckman Coulter, Inc., Siemens AG, Sysmex Corporation, F. Hoffmann-La Roche Ltd, ARKRAY, Inc., Bio-Rad Laboratories, Inc., URIT Medical, Tecodiagnostics among others.

Segmentation:

The global market for Urinalysis by the following sub-categories is presented

· By Product Type

Dipstick

Reagents

Disposables

Biochemical Urine Analyzers

Automated Urine Sediment Analyzers

Point-Of-Care Devices

· By Application

Disease Diagnosis

Pregnancy Tests

· By Test Type

Biochemical Urinalysis

Sediment Urinalysis

· By End Users

Hospitals & Clinics

Diagnostic Laboratories

Research Laboratories and Institutes

Others

· By Geography

North America

South America

Europe

Asia-Pacific

Middle East and Africa

Speak to our Analyst @ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-urinalysis-market

Increasing Prevalence of Urinary tract Infection and Kidney Disease

Urinary tract infection is the most common infection of kidney which is diagnosed by urinalysis test. Febrile UTI is the most common UTI infection that occurs in Childhood. Around 1 in 10 girls and 1 in 30 boys develop UTI by the age of 16. Boys have higher incidence rate of UTI infection while girls have higher incidence rate of recurrent UTI infection. At the age of 7 around 3% girls and 1% boys develop upper UTI infection. Urinalysis market is booming because of the increase in prevalence of urinary tract infection and kidney diseases.

Increasing Geriatric Population

With increasing age, the body’s immune response stops responding and chances of getting bacterial infections or any diseases is very high. According to WHO, in 2015, the world geriatric population aged 60, was 900 Million and by 2050, it is expected to reach 2 billion. With growth in the geriatric population, the urinalysis market is also growing as the chances of getting bacterial infection or UTI infection is more in the elder population.

Some of the major players operating in global urinalysis are Beckman Coulter, Inc, Sysmex India Pvt. Ltd., Siemens Medical Solutions USA, Inc, ARKRAY USA, ACON Laboratories, Inc, Bio-Rad Laboratories, Inc lektronika Kft, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, URIT Medical, F. Hoffman-La Roche Ltd.,, BAYER Healthcare, Kova International, Medline, Menarini, Smart Medical,, Stellar Scientific, Trinity Biotech, Analyticon Biotechnologies, BioPacific Diagnostic and among others

To View Full Sample Report @ https://databridgemarketresearch.com/reports/global-urinalysis-market/

Browse Related Reports:

Global Urinalysis Market-, Global Urinalysis Market By Technology (Sequencing By Synthesis, Sequencing By, Pyrosequencing, Sanger Sequencing and Other Technologies), By Sequencing Method (Shotgun Sequencing, Targeted Gene Sequencing, RNA Sequencing, Whole Genome Sequencing and Other Applications), By Applications (Therapeutics, Genetic Screening, Drug and Biomarker discovery, Personalised Medicine and others), By Research Type (Outsourced and Internal), By End User (Pharmaceutical and Biotechnology Companies and Academia/Research Institutes), By Geography (Europe, North America, Asia-Pacific and Rest of the World )- Industry Trends and Forecast to 2024

https://databridgemarketresearch.com/reports/global-microbiome-sequencing-services-market/

Global Human Microbiome Market- Global Human Microbiome Market By Disease Type (Obesity, Cancer), Application (Therapeutic, Diagnostic), Product Type (Prebiotics, Food, Drugs), Type {(Product Research (Instruments, Consumables), Technology Research (HTS, Omics Technologies)}, Distribution Channel, End Users, Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa, Rest of the World) – Industry Trends and Forecast to 2024

https://databridgemarketresearch.com/reports/global-human-microbiome-market/

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

#Urinalysis Research Report #Urinalysis Market #Global Urinalysis Research Report #Global Urinalysis Market Research Report #Global Urinalysis Industry Analysis

0 notes

riyasharma24mr-blog · 6 years

Text

Global and Chinese Microbiome Sequencing Services Industry, 2018 Market Research Report Market - 24 Market Reports

[2018 Updated Market Report] Global and Chinese Microbiome Sequencing Services Industry, 2018 Market Research Report

Sahil Sharma's insight:

Microbiome Sequencing Services Market 2018–2023 has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The Global and Chinese Microbiome Sequencing Services Industry, 2013–2023 Market Research Report is a professional and indepth study on the current state of the global Microbiome Sequencing Services industry with a focus on the Chinese market. The report provides key statistics on the market status of the Microbiome Sequencing Services manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Download FREE Sample of this Report @ https://www.24marketreports.com/report-sample/microbiome-sequencing-services2018-market-445425

Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2013–2018 market shares for each company.

Through the statistical analysis, the report depicts the global and Chinese total market of Microbiome Sequencing Services industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.

The report then estimates 2018–2023 market development trends of Microbiome Sequencing Services industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Microbiome Sequencing Services Industry before evaluating its feasibility. Overall, the report provides an indepth insight of 2013–2023 global and Chinese Microbiome Sequencing Services industry covering all important parameters.

Any special requirements about this report, please let us know and we can provide custom report.

Get the Complete Report & TOC @ https://www.24marketreports.com/services/microbiome-sequencing-services2018-market-445425

Table of content

Chapter One Introduction of Microbiome Sequencing Services Industry 1.1 Brief Introduction of Microbiome Sequencing Services 1.2 Development of Microbiome Sequencing Services Industry 1.3 Status of Microbiome Sequencing Services Industry

Chapter Two Manufacturing Technology of Microbiome Sequencing Services 2.1 Development of Microbiome Sequencing Services Manufacturing Technology 2.2 Analysis of Microbiome Sequencing Services Manufacturing Technology 2.3 Trends of Microbiome Sequencing Services Manufacturing Technology

Chapter Three Analysis of Global Key Manufacturers 3.1 Company A 3.1.1 Company Profile 3.1.2 Product Information 3.1.3 20132018 Production Information 3.1.4 Contact Information 3.2 Company B 3.2.1 Company Profile 3.2.2 Product Information 3.2.3 20132018 Production Information 3.2.4 Contact Information 3.3 Company C 3.2.1 Company Profile 3.3.2 Product Information 3.3.3 20132018 Production Information 3.3.4 Contact Information 3.4 Company D 3.4.1 Company Profile 3.4.2 Product Information 3.4.3 20132018 Production Information 3.4.4 Contact Information 3.5 Company E 3.5.1 Company Profile 3.5.2 Product Information 3.5.3 20132018 Production Information 3.5.4 Contact Information 3.6 Company F 3.6.1 Company Profile 3.6.2 Product Information 3.5.3 20132018 Production Information 3.6.4 Contact Information 3.7 Company G 3.7.1 Company Profile 3.7.2 Product Information 3.7.3 20132018 Production Information 3.7.4 Contact Information 3.8 Company H 3.8.1 Company Profile

If You Have Any Question Related To This Report Contact Us @ https://www.24marketreports.com/enquire-now/microbiome-sequencing-services2018-market-445425

CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 Fax: (+1) 212 634 4885 Email: [email protected]

0 notes

market-research1-blog · 7 years

Text

Human Microbiome Market 2017 Analysis, Size, Share, Growth and Forecast Report To 2022

The Global Human Microbiome Market Research Report 2017 renders deep perception of the key regional market status of the Human Microbiome Industry on a Global level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, China and Japan.

Free Sample PDF Copy of Human Microbiome Market research report @ https://www.qyresearchgroups.com/request-sample/462450

The report on “Global Human Microbiome Market” is a professional report which provides thorough knowledge along with complete information pertaining to the Human Microbiome industry propos classifications, definitions, applications, industry chain summary, industry policies in addition to plans, product specifications, manufacturing processes, cost structures, etc.

Report Includes:-

Global Human Microbiome market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including

· Merck

�� DuPont

· MicroBiome Therapeutics

· Osel

· Metabiomics Corporation

· Enterome Bioscience

· Yakult

· ViThera Pharmaceuticals

· Vedanta BioSciences

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

· Prebiotics

· Medical Foods

· Drugs

· Probiotics

· Food

· Devices

The report cloaks the market analysis and projection of “Human Microbiome Market” on a regional as well as Global level. The report constitutes qualitative and quantitative valuation by industry analysts, first-hand data, assistance from industry experts along with their most recent verbatim and each industry manufacturers via the market value chain.

The research experts have additionally assessed the in general sales and revenue generation of this particular market. In addition, this report also delivers widespread analysis of root market trends, several governing elements and macro-economic indicators, coupled with market improvements as per every segment. Furthermore, the report contains diverse”.

Browse full report of Global Human Microbiome Market with Table of Content @ https://www.qyresearchgroups.com/report/global-human-microbiome-market-research-report-2017

The report is generically segmented into six parts and every part aims on the overview of the Human Microbiome industry, present condition of the market, feasibleness of the investment along with several strategies and policies. Apart from the definition and classification, the report also discusses the analysis of import and export and describes a comparison of the market that is focused on the trends and development. Along with entire framework in addition to in-depth details, one can prepare and stay ahead of the competitors across the targeted locations.

The fact that this market report renders details about the major market players along with their product development and current trends proves to be very beneficial for fresh entrants to comprehend and recognize the industry in an improved manner. The report also enlightens the productions, sales, supply, market condition, demand, growth, and forecast of the Human Microbiome industry in the global markets.

Every region’s market has been studied thoroughly in this report which deals with the precise information pertaining to the Marketing Channels and novel project investments so that the new entrants as well as the established market players conduct intricate research of trends and analysis in these regional markets. Acknowledging the status of the environment and products’ up gradation, the market report foretells each and every detail.

So as to fabricate this report, complete key details, strategies and variables are examined so that entire useful information is amalgamated together for the understanding and studying the key facts pertaining the global Human Microbiome Industry. The production value and market share in conjunction with the SWOT analysis everything is integrated in this report.

Table of content:

Global Human Microbiome Market Research Report 2017 1 Human Microbiome Market Overview 1.1 Product Overview and Scope of Human Microbiome 1.2 Human Microbiome Segment by Type (Product Category) 1.2.1 Global Human Microbiome Production and CAGR (%) Comparison by Type (Product Category) (2012-2022) 1.2.2 Global Human Microbiome Production Market Share by Type (Product Category) in 2016 1.2.3 Prebiotics 1.2.4 Medical Foods 1.2.5 Drugs 1.2.6 Probiotics 1.2.7 Food 1.2.8 Devices 1.2.9 Other Probiotic Supplements 1.3 Global Human Microbiome Segment by Application 1.3.1 Human Microbiome Consumption (Sales) Comparison by Application (2012-2022) 1.3.2 Diagnostics 1.3.3 Therapeutics 1.4 Global Human Microbiome Market by Region (2012-2022) 1.4.1 Global Human Microbiome Market Size (Value) and CAGR (%) Comparison by Region (2012-2022) 1.4.2 North America Status and Prospect (2012-2022) 1.4.3 Europe Status and Prospect (2012-2022) 1.4.4 China Status and Prospect (2012-2022) 1.4.5 Japan Status and Prospect (2012-2022) 1.4.6 Southeast Asia Status and Prospect (2012-2022) 1.4.7 India Status and Prospect (2012-2022) 1.5 Global Market Size (Value) of Human Microbiome (2012-2022) 1.5.1 Global Human Microbiome Revenue Status and Outlook (2012-2022) 1.5.2 Global Human Microbiome Capacity, Production Status and Outlook (2012-2022) 2 Global Human Microbiome Market Competition by Manufacturers 2.1 Global Human Microbiome Capacity, Production and Share by Manufacturers (2012-2017) 2.1.1 Global Human Microbiome Capacity and Share by Manufacturers (2012-2017) 2.1.2 Global Human Microbiome Production and Share by Manufacturers (2012-2017) 2.2 Global Human Microbiome Revenue and Share by Manufacturers (2012-2017) 2.3 Global Human Microbiome Average Price by Manufacturers (2012-2017) 2.4 Manufacturers Human Microbiome Manufacturing Base Distribution, Sales Area and Product Type 2.5 Human Microbiome Market Competitive Situation and Trends 2.5.1 Human Microbiome Market Concentration Rate 2.5.2 Human Microbiome Market Share of Top 3 and Top 5 Manufacturers 2.5.3 Mergers & Acquisitions, Expansion

If you have any special requirements, please let us know and we will offer you the report as you want.

Make an Enquiry for Human Microbiome Market Research Report @ https://www.qyresearchgroups.com/send-an-enquiry/462450

About Us:

QY Research Groups is a company that simplifies how analysts and decision makers get industry data for their business. Our unique colossal technology has been developed to offer refined search capabilities designed to exploit the long tail of free market research whilst eliminating irrelevant results. QY Research Groups is the collection of market intelligence products and services on the Web. We offer reports and update our collection daily to provide you with instant online access to the world's most complete and current database of expert insights on Global industries, companies, products, and trends.

Email- [email protected]

Web- https://www.qyresearchgroups.com

LinkedIn | Twitter| Facebook

#Human Microbiome Market

0 notes

makingscipub · 7 years

Text

Making microbes public: A workshop report

This is a post by Carmen McLeod who participated in a workshop held at the University of Oxford on 3/4 May 2017 entitled Making Microbes Public. She wrote the original post for the blog of the Interdisciplinary Microbiome Project and it has been reposted here with permission. Carmen is a social anthropologist currently based in the Nottingham Synthetic Biology Research Centre (before that she was part of our Making Science Public programme!). She is moving to the University of Oxford in June 2017 to work on the Good Germs/Bad Germs project and the Oxford Interdisciplinary Microbiome Project (IMP). I am really looking forward to collaborating with the people involved in this project and visiting Carmen in Oxford!

***

Stories about the human microbiome are increasingly being reported in the media and many people – myself included – are fascinated by the relationship between humans and the microscopic ‘bugs’ that live on, in, and around us. I was part of a workshop last week, where a group of interdisciplinary scholars explored this relationship under the theme of ‘Making Microbes Public’.

The workshop began with an afternoon keynote presentation from microbiologist Anne Madden, who was fresh from delivering a TED talk in Vancouver on ‘bugs and bodies’. Anne gave us a frontline view of the work of scientists working with microbes and especially those who closely collaborate with industry partners. Anne describes herself as a ‘microbe wrangler’ and she focusses on how to harness the positive attributes of microbes and apply these in practical ways that will benefit humans.

The next day, we started with a session on ‘Microbes in Society’, and presentations from three anthropologists. Alex Nading began by introducing us to the bureaucratic routines that are part of the day-to-day biopolitics of food sanitation in Nicaragua. He provided a detailed and nuanced account of the interactions between bureaucrats and citizens that occurs during the food handling certification process. Food workers must undergo a blood test and provide a stool sample for analysis and this process is caught up in different layers of informal cultural practices and formal legal requirements. Alex’s narrative of the Nicaraguan public hygiene system reveals how social relations, understandings about microbes, and bureaucracy become intertwined.

Another anthropologist, Amber Benezra, took us on a fascinating journey which linked the work of scientists in North America to the daily life of poorer people living in Dhaka. This presentation revealed there is a problem when microbial science focusses on a ‘technological fix’ such as probiotics for malnutrition, when infrastructure problems such as open drains and other health sanitation issues also need to be addressed. It seems that by working closely with scientists, anthropologists can help resolve some of the disconnections between the laboratory and the realities of everyday life problems. But Amber also raised the question of who holds scientists to account especially when biological science aims to solve problems which are beyond the scope of ‘the biological’.

The third presentation, was from Eben Kirksey who introduced us to bacteria called wolbachia. This is an extremely common parasitic species that lives in insects. This species can reorganise the bodies of their hosts at the microbial level, including changing the sex of their hosts. Interestingly, the ubiquitous and sheer numbers of wolbachia in the world, challenges the notion of heteronormative sex. Eben left us to consider a potential future where polyamorous and promiscuous bacteria like wombachia could survive well beyond human life.

The second session of the day was called ‘Doing Microbiology with Citizens’. This began with Jamie Lorimer and Tim Hodgetts outlining their research on the Good Germs/Bad Germs project. They have been exploring the domestic microbiome through the development of a participatory approach to microbiology. This project involves households in Oxford, going on a ‘kitchen safari’, where participants and the researchers have worked together to design experiments on kitchen microbiomes. Findings from the research suggest it is challenging to move beyond thinking about microbes as pathogens. There has also been positive feedback from some participants who have felt empowered by their involvement in the research design and data collection.

Claire Waterton then provided an overview of her research on the impact of algae (cyanobacteria) blooms on a Lake District community. This interdisciplinary project is tracing the relationship between the microbial organisms who live in the lake and the human residents living alongside it. We heard about how it was difficult to assign blame for the cause of the algae blooms, due to the complex natural and human systems that are in the area. The project set up a collective which enabled different stakeholders’ viewpoints to be incorporated into a complex, and sometimes uncomfortable, debate about community life on the lake.

The next presentation, from social and cultural geographer Emma Roe, described her work engaging health professionals in hand hygiene practices. This research used experimental methods to map the movement of microbes in a hospital setting, including asking two nurses to put UV powder on their gloves and then carry out some routine activities in a ‘mock ward’. Under UV light, all the places that were touched could be mapped. And it turned out that in a 4 minute bed chance, there are over 200 moments of touch! Emma’s research team have produced a video which encourages health professionals to ‘keep washing, keep caring’.

The final presentation before lunch included a gastronomical experience, where we were able to taste a number of fermented yeast products. Josh Evans, who will be coming to Oxford in the fall to commence his doctoral studies, talked about the relationship we have with microbes through food. He explained how fermentation can be understood as a collaboration between humans and microbes. Josh has been working at the Nordic Food Lab in Copenhagen where some ‘convivial experiments’ relating to fermentation techniques are taking place between chefs and scientists (and microbes!) We were given two liquids to taste as well as a teaspoon of dark paste. Although some of us were a bit unsure about tasting these concoctions, they turned out to be rather interesting. (I especially liked the elder vinegar made from fermented elder berries).

After feeding ourselves (and our microbes) at lunch, we had an afternoon of presentations relating to aesthetic interactions between humans and microbes, and science and art, called ‘Microbial Sense-making’. Microbiologist Simon Park explained his interest in ‘microgeography’ which involves using a portable microscope to examine traces left behind of microbial and human interactions within urban environments. Simon has also worked with several artists, such as JoWOnder and Sarah Roberts, to produce microbial art. These artworks incorporate the activities of live bacteria into their creation.

Simon and artist Sarah Craske were then interviewed by Charlotte Sleigh to give us a window of understanding into the process behind producing a series of pieces called Metamorphoses. This intriguing project involved taking an antique (18thC) book and applying a range of scientific and artistic techniques to it. The interview revealed how exciting and truly interdisciplinary this type of project can be. It also revealed some anxieties during the creative process, such as deciding whether to move from non-destructive to destructive analysis of the book. The project also raised questions about the agency of bacteria, and also thinking about whether we can have an ‘ethical relationship’ with microbes.

The final presentation of the workshop was from Adam Bencard, who is a curator at the Copenhagen Medical Museum. Adam provided us with an overview of the preparations that went into a new exhibition called ‘Mind the Gut’ which considers the link between the gut microbiome and the mind. This exhibition has developed through an ‘experiment in co-curation’, involving a mix of artists and scientists, which involved a lengthy planning process over many months. The exhibition itself follows an untraditional format where different rooms are based around ‘action symbols’ or themes that reflect gut/brain relationships at different times. One of the aims of the exhibition is to display the body as ‘messy’ and complex, and to also demonstrate how science itself is an unfinished project. The exhibition will run for at least 3-4 years and is a must see for anyone travelling to Copenhagen!

Image: Bacteria (free download)

The post Making microbes public: A workshop report appeared first on Making Science Public.

via Making Science Public http://ift.tt/2qxT4Pc

#IFTTT #Making Science Public

0 notes

merryjain12-blog · 6 years

Text

Global Urinalysis Market: Full In-depth Analysis by Regional Outlook, Latest Trend, Share, Growth and Forecast to 2025

What Is the Essential of “Global Urinalysis Market” In Medical device Industry.? How It Is Increasing The Market Growth?

For Urinalysis, instruments and consumables such as reagent kits, rapid test kits, analyzers, dipsticks, containers, and pipettes are required.

To Get a Sample Report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-urinalysis-market

Definition:

For Customized Reports and Discounts, Mail us at @ [email protected]

Major Market Competitors:

The global market for Urinalysis by the following sub-categories is presented

By Product Type

Consumables

Dipstick

Reagents

Disposables

Instruments

Biochemical Urine Analyzers

Automated Urine Sediment Analyzers

Point-Of-Care Devices

By Application

Disease Diagnosis

Pregnancy Tests

By Test Type

Biochemical Urinalysis

Sediment Urinalysis

By End Users

Hospitals & Clinics

Diagnostic Laboratories

Research Laboratories and Institutes

Others

By Geography

North America

South America

Europe

Asia-Pacific

Middle East and Africa

Speak to our Analyst @ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-urinalysis-market

Increasing Prevalence of Urinary tract Infection and Kidney Disease

Increasing Geriatric Population

To View Full Sample Report @ https://databridgemarketresearch.com/reports/global-urinalysis-market/

Browse Related Reports:

https://databridgemarketresearch.com/reports/global-microbiome-sequencing-services-market/

https://databridgemarketresearch.com/reports/global-human-microbiome-market/

About Data Bridge Market Research:

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

#Urinalysis Test Research Report #Urinalysis Test opportunities analysis #Urinalysis Test Market #Urinalysis Test Industry Analysis #Urinalysis Test Analysis

0 notes

merryjain12-blog · 6 years

Text

Global Urinalysis Market: Size, Sales, Supply Analysis with Projections to 2025

What Is the Essential of “Global Urinalysis Market” In Medical device Industry.? How It Is Increasing The Market Growth?

Global Urinalysis Market

For Urinalysis, instruments and consumables such as reagent kits, rapid test kits, analyzers, dipsticks, containers, and pipettes are required.

To Get a Sample Report @ http://databridgemarketresearch.com/request-a-sample/?dbmr=global-urinalysis-market

Definition:

For Customized Reports and Discounts, Mail us at @ [email protected]

Major Market Competitors:

The global market for Urinalysis by the following sub-categories is presented

By Product Type

By Application

By Test Type

By End Users

By Geography

Consumables

Dipstick

Reagents

Disposables

Instruments

Biochemical Urine Analyzers

Automated Urine Sediment Analyzers

Point-Of-Care Devices

Disease Diagnosis

Pregnancy Tests

Biochemical Urinalysis

Sediment Urinalysis

Hospitals & Clinics

Diagnostic Laboratories

Research Laboratories and Institutes

Others

North America

South America

Europe

Asia-Pacific

Middle East and Africa

Speak to our Analyst @ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-urinalysis-market

Increasing Prevalence of Urinary tract Infection and Kidney Disease

Increasing Geriatric Population

To View Full Sample Report @ https://databridgemarketresearch.com/reports/global-urinalysis-market/

Browse Related Reports:

https://databridgemarketresearch.com/reports/global-microbiome-sequencing-services-market/

https://databridgemarketresearch.com/reports/global-human-microbiome-market/

About Data Bridge Market Research:

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

#Urinalysis Market Analysis #Urinalysis Market Insights #Urinalysis Market Industry Analysis #Urinalysis Market Insight #Urinalysis Market Forecast #Urinalysis Market Trends #Urinalysis Market Share #Urinalysis Market Size #Urinalysis Market Type #Urinalysis Market #Urinalysis Market Research Report

0 notes